Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Press Releases
Palatin Technologies, Inc.  
December 19, 2024

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathyDemonstrated efficacy at 6 months71% percent of patients achieved a >30%

avatar profile Olean Times Herald

Olean Times Herald


Local & Social